Antimicrobial susceptibility of Streptococcus pneumoniae in Kazakhstan | CMAC

Antimicrobial susceptibility of Streptococcus pneumoniae in Kazakhstan

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2):187-192

Original Article


To study antimicrobial susceptibility of Streptococcus pneumoniae clinical isolates obtained from the patients with community-acquired pneumonia in the Central Kazakhstan.

Materials and Methods.

A total of 186 clinical strains of S. pneumoniae were obtained from the patients with respiratory tract infections in the Central Kazakhstan over the period of 2012–2017. Antimicrobial susceptibility was determined by disk-diffusion method. The isolation and identification of pathogens was performed by routine methods. Antimicrobial (oxacillin, vancomycin, clindamycin, azithromycin, chloramphenicol, tetracycline, rifampin, levofloxacin, linezolid, trimethoprim/sulfamethoxazole) susceptibility testing was performed and interpreted according to CLSI criteria (M100-24).


The resistance rates were the following: oxacillin – 4.2%, azithromycin – 12.4%, tetracycline – 71.1%, chloramphenicol – 7.8%, trimethoprim/sulfamethoxazole – 57.1%, rifampin – 5.6% and levofloxacin – 3.4%. There were no S. pneumoniae isolates resistant to linezolid or vancomycin.


The amoxicillin is recommended as a drug of choice for antimicrobial therapy of pneumococcal respiratory tract infections.

0 Abstract
0 Crossref citations